Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc., situated in La Palma, California, is an immuno-oncology firm actively engaged in clinical trials, dedicated to pioneering innovative treatments for various cancers.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Liminatus Pharma, Inc. Warrants
+13.96%$0.0400
Prev close$0.0351+13.96%Close$0.0400
Mkt Cap$54K
EV$1.19M
Float-
O/S1.34M
VOL251 sh
$ Vol$10
RVOL1.31×
Inst Own-
SI0.1%
Net Cash/Sh-$0.82
Dilution
MCap$54KFloat-O/S1.34M
Dilution
Financials Summary
Revenue$0
Net Income-$10.21M
Total Assets$513K
Free Cash Flow-$9.98M
Debt & Equity
Total Debt$1.44M
Total Equity-$9.81M
Shares Outstanding
Short Interest
No short interest data available.
Split History
No splits on record
Nothing in LIMNW's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$513K
Liabilities$10.33M
Accounts Receivable$0
Accounts Payable$582K
Inventory$0
PP&E (Net)$12K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - |
| Research and Development | $0 | $2.69M | $3.76M | $1.85M | $3.8M |
| Selling, General, and Administrative | $2.97M | $645K | $1.06M | $856K | $197K |
| Other | $0 | -$424K | -$2.23M | $0 | -$1.46M |
| Total Operating Expenses | $2.97M | $2.91M | $2.59M | $2.71M | $2.53M |
| Operating Income (EBIT) | -$2.97M | -$2.91M | -$2.59M | -$2.71M | -$2.53M |
| Operating Margin | - | - | - | - | - |
| Interest Expense | $216K | $138K | $175K | $219K | $0 |
| Interest Income | $77K | $138K | $10K | $0 | $17K |
| Other Income (Expense) | -$7.24M | $21K | $1.39M | -$219K | $6.9M |
| Income Before Tax (EBT) | -$10.21M | -$2.89M | -$1.19M | -$2.93M | $4.37M |
| Income Tax Expense | $0 | $19K | $34K | $0 | $0 |
| Net Income | -$10.21M | -$2.9M | -$1.23M | -$2.93M | $4.37M |
| Net Income Margin | - | - | - | - | - |
| Supplementary Data | |||||
| EPS | -21.50 | -20.00 | -7.50 | -4.12 | 6.50 |
| Diluted EPS | -21.50 | -20.00 | -7.50 | -4.12 | 6.50 |
| Weighted Average OS | 475,071 | 143,832 | 160,251 | 688,565 | 690,000 |
| EBITDA | -$9.99M | -$2.75M | -$1.09M | -$2.71M | $4.37M |
| EBITDA Margin | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $338K | $805K | $434K | $5.05M | $336K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $338K | $805K | $434K | $5.05M | $336K |
| Accounts Receivable | $0 | $6K | $945K | $100K | $1K |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $163K | $2K | -$1.17M | -$6.47M | $84K |
| Total Current Assets | $501K | $813K | $211K | $361K | $422K |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $12K | $0 | $1K | $1K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $2.02M | $4.29M | $15.13M | $276.02M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | -$1K | -$1K | $0 |
| Total Long-Term Assets | $12K | $2.02M | $4.29M | $15.13M | $276.02M |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $513K | $2.83M | $4.5M | $15.49M | $276.44M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $582K | $1.48M | $933K | $508K | $419K |
| Short-Term Debt | $1.44M | $5.12M | $16.05M | $16.5M | $90K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $2.08M | -$12.88M | -$14.06M | $871K |
| Total Current Liabilities | $10.3M | $8.68M | $5.16M | $3.59M | $1.38M |
| Long-Term Liabilities | |||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $29K | $10.02M | $10.04M | $10.6M | $20.19M |
| Total Long-Term Liabilities | $29K | $10.02M | $10.04M | $10.6M | $20.19M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.33M | $18.7M | $15.19M | $14.19M | $21.57M |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $3K | $1.76M | $4.05M | $15.13M | $276M |
| Retained Earnings | -$38.87M | -$17.52M | -$14.88M | -$13.97M | -$21.13M |
| Comprehensive Income & Other | $0 | -$161K | $0 | $0 | $0 |
| Other Stockholders' Equity | $29.05M | -$109K | $140K | $140K | $0 |
| Total Equity | -$9.81M | -$15.87M | -$10.69M | $1.29M | $254.87M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $513K | $2.83M | $4.5M | $15.49M | $276.44M |
| Supplementary Data | |||||
| Total Debt | $1.44M | $5.12M | $16.05M | $16.5M | $90K |
| Net Debt | $1.1M | $4.32M | $15.62M | $11.45M | -$246K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$10.21M | -$2.9M | -$4.98M | -$2.93M | $4.37M |
| Depreciation & Amortization | $2K | $0 | $0 | $1K | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | -$3.43M | $48K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$4.04M | $0 | $425K | $89K | $0 |
| Other Working Capital | $478K | -$93K | $1.21M | $1.07M | $1.32M |
| Total Working Capital Change | -$6.98M | -$45K | $1.64M | $1.16M | $1.32M |
| Other Non-Cash Items | $7.23M | -$158K | $0 | $899K | -$6.9M |
| Net Cash from Operating | -$9.96M | -$3.11M | -$3.35M | -$869K | -$1.22M |
| Investing Activities | |||||
| Capital Expenditures | -$13K | $0 | $0 | $0 | $0 |
| Acquisitions | $4.44M | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | -$189K | -$121K | $0 | -$276M |
| Sales of Investments | $0 | $2.16M | $0 | $0 | $0 |
| Other Investing Activities | -$5.22M | $0 | -$698K | $0 | $0 |
| Net Cash from Investing | -$788K | $1.97M | -$819K | $0 | -$276M |
| Financing Activities | |||||
| Debt Repaid | - | - | - | - | - |
| Common Stock Issuance | $10.56M | $0 | $0 | $4.2M | $283.07M |
| Common Stock Repurchases | $0 | -$1.8M | -$10.66M | -$700K | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$2.56M | $0 | $10.66M | $0 | -$5.52M |
| Net Cash from Financing | $11.03M | $1.05M | -$450K | $5.92M | $277.55M |
| Forex Effect | $0 | $739K | $0 | $0 | $0 |
| Net Change in Cash | $281K | $648K | -$4.61M | $5.05M | $336K |
| Supplementary Data | |||||
| Operating Cash Flow | -$9.96M | -$3.11M | -$3.35M | -$869K | -$1.22M |
| Capital Expenditure | -$13K | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$9.98M | -$3.11M | -$3.35M | -$869K | -$1.22M |
| Cash at Beginning | $56K | $156K | $5.05M | $336K | $0 |
| Cash at End | $338K | $805K | $434K | $5.38M | $336K |